SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

        Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
                                      1934

Date of Report (Date of earliest event reported) May 30, 2000

                                   ENZON, INC.
             (Exact name of registrant as specified in its charter)



          Delaware                   0-12957                        22-237286
(State or other jurisdiction       (Commission                    (IRS Employer
      of incorporation)           File Number)                   Identification)


                20 Kingsbridge Road, Piscataway, New Jersey 08854
               (Address of principal executive offices) (Zip Code)


        Registrant's telephone number, including area code (732) 980-4500


           ___________________________________________________________
          (Former name or former address, if changed since last report)






Item 5. Other Events

     On May 30, 2000,  Schering-Plough  Corporation  announced that the European
Union's   Commission  of  the  European   Communities   has  granted   marketing
authorization  to  PEGINTRON(TM)   (peginterferon   alfa-2b)  as  a  once-weekly
monotherapy  for  adult  patients  with  chronic  hepatitis  C.  PEGINTRON  is a
longer-acting  form  of  Schering-Plough's   INTRON(R)  A  (interferon  alfa-2b,
recombinant)   Injection,   developed  using  proprietary  Enzon  PEG-technology
licensed to Schering-Plough.

     Commission approval of the centralized  application of PEGINTRON results in
a single Marketing Authorization with unified labeling that is immediately valid
in all 15 EU-Member  States.  The  Commission's  decision  follows the product's
unanimous recommendation for approval in February 2000 by the EU's Committee for
Proprietary  Medicinal Products (CPMP) of the European Agency for the Evaluation
of Medicinal Products (EMEA).

     PEGINTRON  will be  introduced  upon  receiving  pricing  approvals,  where
necessary, from individual EU countries.

     PEGINTRON  is  indicated  as   monotherapy   in  case  of   intolerance  or
contraindication   to  ribavirin  for  the  treatment  of  adult  patients  with
histologically  proven  chronic  hepatitis C who have serum  markers  indicating
virus replication e.g., those patients who have elevated transaminases (elevated
enzyme   levels   indicating   ongoing   liver   inflammation)   without   liver
decompensation and who are positive for serum HCV-RNA (hepatitis C viral RNA) or
anti-HCV (antibodies to hepatitis C virus).

     The approved  labeling in the EU for PEGINTRON  indicates  that the optimal
treatment for chronic  hepatitis C is considered to be the  administration  of a
combination of interferon alfa-2b with ribavirin. The safety and efficacy of the
combination of PEGINTRON and ribavirin has not yet been documented.

     In  addition  to this  European  approval,  Schering-Plough  is  conducting
clinical  trials for other  therapeutic  indications and seeking other marketing
approvals for PEG-INTRON. Phase III clinical trials are on-going with PEG-INTRON
in  combination  therapy with  REBETOL(R)  (Ribavirin,  USP) for hepatitis C. In
addition, PEG-INTRON is in Phase III clinical trials for two cancer indications,
malignant melanoma and chronic myelogenous  leukemia,  as well as in early stage
trials for various solid tumors. On December 23, 1999 Schering-Plough  submitted
a Biologics License Application to the U.S. Food and Drug Administration seeking
marketing  approval in the U.S. for PEG-INTRON as a once-weekly  monotherapy for
the treatment of chronic hepatitis C.

     Certain statements made herein related to potential  government  approvals,
market potential,  commercialization  and sales revenues of medical products and
biologics,  as  well  as  their  therapeutic   applications  and  outcomes,  are
forward-looking  and are made  pursuant  to the safe  harbor  provisions  of the
Securities  Litigation  Reform Act of 1995.  Such  statements  involve risks and
uncertainties,  which  may  differ  materially  from  those  set  forth in these
statements. In addition, the economic, competitive, governmental,  technological
and other factors identified in Enzon's filings with the Securities and Exchange
Commission could affect such results.






                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Dated: June 6, 2000

           ENZON, INC.
     ----------------------
          (Registrant)


                                        By:  /s/ KENNETH J. ZUERBLIS
                                             -----------------------------------
                                             Kenneth J. Zuerblis
                                             Vice President,
                                             Finance and Chief Financial Officer



                                        2